Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Filing Registration
  6. Priority Review

Priority Review

Evaluate

Thumbnail
June 09, 2023

EHA 2023 – Crispr sets a date with the US regulator

Thumbnail
May 15, 2023

The waxing and waning of the speedy approval

As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?

Article image
Vantage logo
December 09, 2022

Not so fast for some accelerated approvals

The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.

Article image
Vantage logo
April 14, 2022

Is biopharma getting better at accelerated approval conversions?

Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.

Article image
Vantage logo
June 24, 2021

Lilly rushes through wide-open US Alzheimer’s floodgates

Article image
Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.

Article image
Vantage logo
May 06, 2020

The Celgene contingent value right comes down to the wire

Article image
Vantage logo
March 27, 2020

Holding a contingent value right in uncertain times

Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.

Article image
Vantage logo
February 18, 2020

FDA keeps the faith in surrogate endpoints

The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.

Article image
Vantage logo
February 17, 2020

Solving the mystery of Vifor’s new voucher

Article image
Vantage logo
November 16, 2018

Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval

Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up